(S)-(+)-Epichlorohydrin
| Title | Journal |
|---|---|
| Lanthanum carbonate reduces urine phosphorus excretion: evidence of high-capacity phosphate binding. | Renal failure 20121201 |
| Npt2b deletion attenuates hyperphosphatemia associated with CKD. | Journal of the American Society of Nephrology : JASN 20120928 |
| Enantioselective hydrolysis of epichlorohydrin using whole Aspergillus niger ZJB-09173 cells in organic solvents. | Journal of biosciences 20120901 |
| Dietary phosphate modifies lifespan in Drosophila. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120901 |
| Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients. | Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20120901 |
| Spontaneous carbonate formation in an amorphous, amine-rich, polymeric drug substance: sevelamer HCl product quality. | Journal of pharmaceutical sciences 20120801 |
| Phosphate binders in CKD: bad news or good news? | Journal of the American Society of Nephrology : JASN 20120801 |
| Effects of phosphate binders in moderate CKD. | Journal of the American Society of Nephrology : JASN 20120801 |
| Case of proximal calciphylaxis with protein S deficiency, successfully treated with multimodality therapy. | The Journal of dermatology 20120701 |
| Enhancement and restriction of chain motion in polymer networks. | International journal of pharmaceutics 20120701 |
| Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study. | Clinical nephrology 20120701 |
| [Kidney and bone update : the 5-year history and future of CKD-MBD. Pharmacoeconomics in the field of CKD-MBD]. | Clinical calcium 20120701 |
| Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. | Clinical journal of the American Society of Nephrology : CJASN 20120601 |
| Effect of gastric acid suppression with pantoprazole on the efficacy of sevelamer hydrochloride as a phosphate binder in haemodialysis patients: a pilot study. | Nephrology (Carlton, Vic.) 20120501 |
| Non-systemic drugs: a critical review. | Current pharmaceutical design 20120401 |
| Potential influence of sevelamer hydrochloride on responsiveness to erythropoiesis-stimulating agents in haemodialysis patients. | Nephrology (Carlton, Vic.) 20120301 |
| Mortality in kidney disease patients treated with phosphate binders: a randomized study. | Clinical journal of the American Society of Nephrology : CJASN 20120301 |
| Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120201 |
| Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20120201 |
| Potential interaction between sevelamer and fat-soluble vitamins: a hypothesis. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20120201 |
| Directed evolution strategies for enantiocomplementary haloalkane dehalogenases: from chemical waste to enantiopure building blocks. | Chembiochem : a European journal of chemical biology 20120102 |
| Role of uremic toxins and oxidative stress in the development of chronic kidney disease-mineral and bone disorder. | Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20120101 |
| Effects of phosphonoformic acid and renagel on renal type IIa sodium-dependent phosphate cotransporter mRNA expression in hyperphosphatemia rats. | Renal failure 20120101 |
| Treatment of gabapentin-induced myoclonus with continuous renal replacement therapy. | Indian journal of nephrology 20120101 |
| Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. | PloS one 20120101 |
| Roles of major facilitator superfamily transporters in phosphate response in Drosophila. | PloS one 20120101 |
| Lanthanum carbonate: a postmarketing observational study of efficacy and safety. | Journal of nephrology 20120101 |
| Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects. | Nephron. Clinical practice 20120101 |
| Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients. | PloS one 20120101 |
| Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease. | International journal of biological sciences 20120101 |
| Liver Transplantation because of Acute Liver Failure due to Heme Arginate Overdose in a Patient with Acute Intermittent Porphyria. | Case reports in gastroenterology 20120101 |
| Left ventricular diastolic dysfunction in dialysis patients assessed by novel speckle tracking strain rate analysis: prevalence and determinants. | International journal of nephrology 20120101 |
| Phosphorus and nutrition in chronic kidney disease. | International journal of nephrology 20120101 |
| Assessment of phosphate binding by sevelamer carbonate powder for oral suspension mixed in foods. | Nephrology nursing journal : journal of the American Nephrology Nurses' Association 20120101 |
| Recurrent hyperphosphatemic tumoural calcinosis. | BMJ case reports 20120101 |
| Effect of post-dilutional on-line haemodiafiltration on serum calcium, phosphate and parathyroid hormone concentrations in uraemic patients. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20111201 |
| Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience. | Artificial organs 20111201 |
| Multi-intervention management of calciphylaxis: a report of 7 cases. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20111201 |
| Pharmacotherapy of chronic kidney disease and mineral bone disorder. | Expert opinion on pharmacotherapy 20111201 |
| CKD-mineral and bone disorder: core curriculum 2011. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20111201 |
| C-reactive protein levels are associated with arterial media calcification in nondiabetic patients with end-stage renal disease on long-term hemodialysis. | Clinical nephrology 20111201 |
| Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20111201 |
| Impact of non-traditional phosphate binders and cinacalcet on haemodialysis patient biochemistry, pill burden and cost. | Nephrology (Carlton, Vic.) 20111101 |
| The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20111101 |
| Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride. | Nephrology (Carlton, Vic.) 20111101 |
| Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia? | European review for medical and pharmacological sciences 20111101 |
| A study of maintenance therapy after intravenous maxacalcitol for secondary hyperparathyroidism. | Clinical nephrology 20111001 |
| Effectiveness and cost-efficacy of phosphate binders in hemodialysis. | Annals of nutrition & metabolism 20111001 |
| Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: results from the French ARNOS study. | Hemodialysis international. International Symposium on Home Hemodialysis 20111001 |
| Pharmacology, efficacy and safety of oral phosphate binders. | Nature reviews. Nephrology 20110906 |
| Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. | Clinical journal of the American Society of Nephrology : CJASN 20110901 |
| Vascular calcification in chronic kidney disease: mechanisms and clinical implications. | Iranian journal of kidney diseases 20110901 |
| Effects of lowering dialysate calcium concentrations on arterial stiffness in patients undergoing hemodialysis. | The Korean journal of internal medicine 20110901 |
| Cardiovascular MRI in clinical trials: expanded applications through novel surrogate endpoints. | Heart (British Cardiac Society) 20110815 |
| A randomized controlled trial of oral phosphate binders in the treatment of pseudoxanthoma elasticum. | Journal of the American Academy of Dermatology 20110801 |
| Diffuse uremic tumoral calcinosis in a patient on long-term hemodialysis. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110801 |
| Biomechanical properties of bones from rats treated with sevelamer. | Collegium antropologicum 20110601 |
| Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders. | Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20110501 |
| The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110501 |
| Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20110501 |
| Mineral metabolism management in Canadian peritoneal dialysis patients. | Clinical nephrology 20110501 |
| Efficient total synthesis of (+)-dihydropinidine, (-)-epidihydropinidine, and (-)-pinidinone. | Journal of natural products 20110425 |
| Cardiovascular outcome in asymptomatic hemodialysis patients submitted to aggressive medical therapy: results of a four-year follow-up. | Minerva cardioangiologica 20110401 |
| Is combined calcium/magnesium phosphate binder really noninferior to sevelamer hydrochloride? | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110401 |
| Cardiovascular risk factors in chronic kidney disease: does phosphate qualify? | Kidney international. Supplement 20110401 |
| Uremic toxins and oral adsorbents. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20110401 |
| Sevelamer use and incidence of peritonitis in peritoneal dialysis. | Wiener klinische Wochenschrift 20110401 |
| Mineral metabolism: Sevelamer slows calcification and reduces levels of AGEs. | Nature reviews. Nephrology 20110401 |
| Does the choice of phosphate binder affect trace element levels in chronic kidney disease patients treated by regular haemodialysis? | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110301 |
| Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20110301 |
| Pharmacology of the phosphate binder, lanthanum carbonate. | Renal failure 20110301 |
| Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. | The Cochrane database of systematic reviews 20110216 |
| Sevelamer prescriptions after reporting of the Dialysis Clinical Outcomes Revisited (DCOR) trial findings: An analysis of 5,495 patients receiving maintenance dialysis in Ontario, Canada. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20110201 |
| Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20110201 |
| Development and validation of rapid ion-chromatographic method with conductivity detection for trace level determination of allylamine in sevelamer drug substances. | Journal of pharmaceutical and biomedical analysis 20110105 |
| Consequences and therapy of the metabolic acidosis of chronic kidney disease. | Pediatric nephrology (Berlin, Germany) 20110101 |
| Interprovincial differences in the achievement of K/DOQI targets of mineral metabolism in Canada. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110101 |
| Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. | Nephron. Clinical practice 20110101 |
| Effect of sevelamer hydrochloride exposure on carotid intima media thickness in hemodialysis patients. | Nephron. Clinical practice 20110101 |
| Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. | Kidney international 20110101 |
| Comparative effectiveness of calcium-containing phosphate binders in incident U.S. dialysis patients. | Clinical journal of the American Society of Nephrology : CJASN 20110101 |
| Phosphate binder is not phosphate binder! Sevelamer may be different! | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110101 |
| Reduction of hyperphosphatemia is related with the reduction of C-reactive protein in dialysis patients. Study in sevelamer-resistant dialysis patients treated with chitosan chewing gum as salivary phosphate binder. | Renal failure 20110101 |
| [Chronic kidney disease and atherosclerosis]. | Nihon rinsho. Japanese journal of clinical medicine 20110101 |
| Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study. | Wiener klinische Wochenschrift 20110101 |
| Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial. | Trials 20110101 |
| Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study. | Clinical drug investigation 20110101 |
| Cardiorenal syndrome type 4-cardiovascular disease in patients with chronic kidney disease: epidemiology, pathogenesis, and management. | International journal of nephrology 20110101 |
| New-onset headache in an elderly man with uremia that improved only after correction of hyperphosphatemia ('uremic headache'): a case report. | Journal of medical case reports 20110101 |
| Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. | BMJ (Clinical research ed.) 20110101 |
| Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? | BMC nephrology 20110101 |
| The Effect of Paricalcitol on Vascular Calcification and Cardiovascular Disease in Uremia: Beyond PTH Control. | International journal of nephrology 20110101 |
| Dyslipidemia associated with chronic kidney disease. | The open cardiovascular medicine journal 20110101 |
| Association of Serum Phosphate and Related Factors in ESRD-Related Vascular Calcification. | International journal of nephrology 20110101 |
| Phosphate Metabolism in CKD Stages 3-5: Dietary and Pharmacological Control. | International journal of nephrology 20110101 |
| Pharmacological management of cardiorenal syndromes. | International journal of nephrology 20110101 |
| Arterial stiffness in chronic kidney disease: the usefulness of a marker of vascular damage. | International journal of nephrology 20110101 |
| Use of percutaneous ethanol injection therapy for recurrent secondary hyperparathyroidism after subtotal parathyroidectomy. | International journal of nephrology 20110101 |
| Effects of the Use of Non-Calcium Phosphate Binders in the Control and Outcome of Vascular Calcifications: A Review of Clinical Trials on CKD Patients. | International journal of nephrology 20110101 |
| Calcific uremic arteriolopathy in peritoneal dialysis populations. | International journal of nephrology 20110101 |
| [Effect of non-calcium-based phosphate binders on vascular calcifications in patients on hemodialysis: clinical experience and hypotheses]. | Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20110101 |
| [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients]. | Wiadomosci lekarskie (Warsaw, Poland : 1960) 20110101 |
| Vascular and valvular calcification in chronic peritoneal dialysis patients. | International journal of nephrology 20110101 |
| Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure. | Hippokratia 20110101 |
| Renal artery stenosis in kidney transplants: assessment of the risk factors. | Vascular health and risk management 20110101 |
| Regression of vascular calcification in a patient treated with cinacalcet: a case report. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20110101 |
| Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study. | BMC nephrology 20110101 |
| Carotid artery calcification at the initiation of hemodialysis is a risk factor for cardiovascular events in patients with end-stage renal disease: a cohort study. | BMC nephrology 20110101 |
| Lower gastrointestinal bleeding in chronic hemodialysis patients. | International journal of nephrology 20110101 |
| Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis. | Indian journal of nephrology 20110101 |
| Levothyroxine and sevelamer: listen to the patient. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20110101 |
| Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia. | Health economics review 20110101 |
| Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3-4. | International urology and nephrology 20101201 |
| Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20101201 |
| Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20101101 |
| Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V). | Expert opinion on pharmacotherapy 20101101 |
| [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality]. | Clinical calcium 20101101 |
| FGF-23: More than a regulator of renal phosphate handling? | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20101001 |
| 'Real-World' use of cinacalcet for managing SHPT in different European countries: analysis of data from the ECHO observational study. | Clinical nephrology 20100901 |
| Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients. | Journal of the Formosan Medical Association = Taiwan yi zhi 20100901 |
| Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100801 |
| Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. | Leukemia research 20100701 |
| Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders. | Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20100701 |
| Impact of phosphate binder type on coronary artery calcification in hemodialysis patients. | Clinical nephrology 20100701 |
| Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis. | Pharmacotherapy 20100701 |
| [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). The impact of CKD-MBD on mortality]. | Clinical calcium 20100701 |
| [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Parathyroid interventions: final one piece in the management of uremic SHPT patients]. | Clinical calcium 20100701 |
| Homocysteine and folic acid levels in hemodialysis patients treated with sevelamer hydrochloride. | Clinical nephrology 20100601 |
| Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20100601 |
| Sevelamer carbonate. No better than sevelamer hydrochloride. | Prescrire international 20100601 |
| Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. | Clinical journal of the American Society of Nephrology : CJASN 20100501 |
| Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients. | American journal of nephrology 20100501 |
| [Secondary osteoporosis UPDATE. Therapy for bone-mineral disease in CKD-5D patients]. | Clinical calcium 20100501 |
| Is excess calcium harmful to health? | Nutrients 20100501 |
| Oral phosphate binders in patients with kidney failure. | The New England journal of medicine 20100408 |
| Sevelamer 'carbonate': what's in a name? | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100401 |
| Novel markers of left ventricular hypertrophy in uremia. | American journal of nephrology 20100401 |
| New therapies: calcimimetics, phosphate binders and vitamin D receptor activators. | Pediatric nephrology (Berlin, Germany) 20100401 |
| [Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy]. | Nephrologie & therapeutique 20100401 |
| Development and utility of a multi-dimensional grid to assess individual mineral metabolism control in hemodialysis patients: A potential aid for therapeutic decision making? | Hemodialysis international. International Symposium on Home Hemodialysis 20100401 |
| Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia? | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20100401 |
| Report of an unusual case with severe fecal impaction responding to medication therapy. | Journal of neurogastroenterology and motility 20100401 |
| Can we reduce the cardiovascular risk in peritoneal dialysis patients? | Indian journal of nephrology 20100401 |
| Phosphate binders in CKD: chalking out the differences. | Pediatric nephrology (Berlin, Germany) 20100301 |
| Are lipoprotein disturbances in chronic hemodialyzed patients only renal failure related? | Collegium antropologicum 20100301 |
| Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients. | Pediatric nephrology (Berlin, Germany) 20100201 |
| Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? | Clinical journal of the American Society of Nephrology : CJASN 20100201 |
| A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20100201 |
| Interventions for bone disease in children with chronic kidney disease. | The Cochrane database of systematic reviews 20100120 |
| Sevelamer carbonate. | The Annals of pharmacotherapy 20100101 |
| Metal ion and vitamin adsorption profiles of phosphate binder ion-exchange resins. | Clinical nephrology 20100101 |
| Ten-year experience with sevelamer and calcium salts as phosphate binders. | Clinical journal of the American Society of Nephrology : CJASN 20100101 |
| The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research. | The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20100101 |
| Impact of calcium, phosphate, PTH abnormalities and management on mortality in hemodialysis: results from the RISCAVID study. | Journal of nephrology 20100101 |
| Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer? | Journal of nephrology 20100101 |
| Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia. | Blood purification 20100101 |
| Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients. | Nephron. Clinical practice 20100101 |
| A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice. | Journal of nephrology 20100101 |
| Risk factors of one year increment of coronary calcifications and survival in hemodialysis patients. | BMC nephrology 20100101 |
| [Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20100101 |
| Model-Based Analysis of FGF23 Regulation in Chronic Kidney Disease. | Gene regulation and systems biology 20100101 |
| [Analysis of the efficacy and factors influencing the response of secondary hyperparathyroidism patients on hemodialysis to cinacalcet]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20100101 |
| Failed Switching off in the MIBI-Parathyroid Scintigraphy in a Dialyzed Patient with Secondary Hyperparathyroidism Responsive to Cinacalcet Therapy. | International journal of endocrinology 20100101 |
| Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. | BMJ (Clinical research ed.) 20100101 |
| Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches. | Oxidative medicine and cellular longevity 20100101 |
| Sevelamer carbonate reduces inflammation and endotoxemia in an animal model of uremia. | Blood purification 20100101 |
| The control of hyperphosphatemia in renal failure: between vascular calcification and inflammation. | Blood purification 20100101 |
| Determination of residual epichlorohydrin in sevelamer hydrochloride by static headspace gas chromatography with flame ionization detection. | Scientia pharmaceutica 20100101 |
| Inflammation as a target for improving health in chronic kidney disease. | F1000 medicine reports 20100101 |
| End-stage renal disease. | BMJ clinical evidence 20100101 |
| New and improved strategies for the treatment of gout. | International journal of nephrology and renovascular disease 20100101 |
| Effects of acute variation of dialysate calcium concentrations on arterial stiffness and aortic pressure waveform. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20091201 |
| A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20091201 |
| Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data. | Clinical journal of the American Society of Nephrology : CJASN 20091201 |
| Uremic toxins originating from colonic microbial metabolism. | Kidney international. Supplement 20091201 |
| Endotoxin-binding affinity of sevelamer: a potential novel anti-inflammatory mechanism. | Kidney international. Supplement 20091201 |
| Sevelamer and the bone-vascular axis in chronic kidney disease: bone turnover, inflammation, and calcification regulation. | Kidney international. Supplement 20091201 |
| Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease. | Drugs 20091112 |
| The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20091001 |
| Sevelamer versus calcium-based phosphate binders in chronic kidney disease: what should we conclude from the evidence to date? | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20091001 |
| Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20091001 |
| Treating mineral metabolism disorders in patients undergoing long hemodialysis: a search for an optimal strategy. | Hemodialysis international. International Symposium on Home Hemodialysis 20091001 |
| Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. | Clinical nephrology 20091001 |
| A bitter pill to swallow. | Clinical nephrology 20091001 |
| Hypertension and hyperparathyroidism are associated with left ventricular hypertrophy in patients on hemodialysis. | Indian journal of nephrology 20091001 |
| Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090901 |
| Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study. | Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20090901 |
| Improvement in secondary hyperparathyroidism due to drug adherence monitoring in dialysis patients. | Clinical nephrology 20090901 |
| Sevelamer reduces the efficacy of many other drugs. | Prescrire international 20090801 |
| Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols. | Pediatric nephrology (Berlin, Germany) 20090701 |
| Predictors of anemia in patients on hemodialysis. | Hemodialysis international. International Symposium on Home Hemodialysis 20090701 |
| Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients. | Hemodialysis international. International Symposium on Home Hemodialysis 20090701 |
| Calciphylaxis in chronic renal failure: An approach to risk factors. | Indian journal of nephrology 20090701 |
| [Clinical aspect of recent progress in phosphate metabolism. Phosphate retension, a powerful risk factor for mortality in chronic kidney disease (CKD)]. | Clinical calcium 20090601 |
| [Clinical aspect of recent progress in phosphate metabolism. Management of hyperphosphagtemia]. | Clinical calcium 20090601 |
| Oral phosphate binders. | Kidney international 20090501 |
| Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. | Pharmacotherapy 20090501 |
| Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. | British journal of pharmacology 20090401 |
| [Chronic kidney disease (CKD) and bone. Control of CKD-MBD from the viewpoint of the medical cost]. | Clinical calcium 20090401 |
| [Chronic kidney disease (CKD) and bone. Targets of serum calcium, phosphate, and parathyroid hormone levels and their controls in maintenance dialysis patients]. | Clinical calcium 20090401 |
| [Chronic kidney disease (CKD) and bone. Vascular calcification in CKD]. | Clinical calcium 20090401 |
| [The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease]. | Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20090401 |
| [Cinacalcet in the treatment of secondary hyperparathyreoidism in a child with chronic kidney disease--case report]. | Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20090401 |
| Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. | Lancet (London, England) 20090321 |
| Long-term outcome of chronic dialysis in children. | Pediatric nephrology (Berlin, Germany) 20090301 |
| Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090301 |
| Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090301 |
| The use of phosphate binders: data from contributors to the European Practice Database. | Journal of renal care 20090301 |
| Update on the treatment of chronic kidney disease-mineral and bone disorder. | Journal of renal care 20090301 |
| Oral phosphate binders for the management of serum phosphate levels in dialysis patients. | Journal of renal care 20090301 |
| [Management of phosphate in chronic kidney disease--Chemistry and history of phosphate binder]. | Clinical calcium 20090201 |
| [Management of hyperphosphatemia ; phosphate-binder]. | Clinical calcium 20090201 |
| [Management of phosphate in chronic kidney disease--Clinical trials of lanthanum carbonate]. | Clinical calcium 20090201 |
| [Use of phosphate binder in predialysis patients]. | Clinical calcium 20090201 |
| [Novel phosphate binders under development]. | Clinical calcium 20090201 |
| [To facilitate the compliance of phosphate binder for the control of hyperphosphatemia in chronic kidney disease patients]. | Clinical calcium 20090201 |
| Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients. | Clinical nephrology 20090201 |
| The control of hyperphosphatemia in chronic kidney disease: which phosphate binder? | The International journal of artificial organs 20090201 |
| Effect of sevelamer hydrochloride on bone in experimental uremic rats. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20090201 |
| Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20090101 |
| Diaminobutane (DAB) dendrimers are potent binders of oral phosphate. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20090101 |
| Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090101 |
| Phosphate binders in chronic kidney disease and end-stage renal disease: a patient-centered approach. | Seminars in dialysis 20090101 |
| Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients on sevelamer hydrochloride: which dialysate calcium concentration to use? | Blood purification 20090101 |
| Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification. | American journal of nephrology 20090101 |
| Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer. | Hormone research 20090101 |
| Associations between oxidized LDL to LDL ratio, HDL and vascular calcification in the feet of hemodialysis patients. | Journal of Korean medical science 20090101 |
| [Treating distal calciphylaxis with therapy associated with sevelamer and bisphosphonates]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20090101 |
| Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients. | Internal medicine (Tokyo, Japan) 20090101 |
| [Prescription of phosphorus binders and calcitriol for chronic hemodialysis patients]. | Revista da Associacao Medica Brasileira (1992) 20090101 |
| [Multiple peritrochanteric and pubic calcifications in a young woman on hemodialysis with severe renal osteodystrophy successfully treated with sevelamer+cinacalcet+paracalcitol combination therapy]. | Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20090101 |
| A 44 year-old lady with chronic renal disease and intractable ulcers: a case report. | International archives of medicine 20090101 |
| Strategies to manage low-bone turnover. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20090101 |
| Cardiovascular disease in patients with chronic kidney disease. | Vascular health and risk management 20090101 |
| African American female with renal failure presenting with skin lesions: a case report. | Cases journal 20090101 |
| A 60-year-old man with chronic renal failure and a costal mass: a case report and review of the literature. | Journal of medical case reports 20090101 |
| Vascular calcification and QT interval in incident hemodialysis patients. | Journal of nephrology 20090101 |
| Lanthanum associated abnormal liver function tests in two patients on dialysis: a case report. | Journal of medical case reports 20090101 |
| Effectiveness and cost-efficiency of phosphate binders in hemodialysis. | GMS health technology assessment 20090101 |
| Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate. | International journal of nephrology and renovascular disease 20090101 |
| Abdominal aortic calcification in dialysis patients: results of the CORD study. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20081201 |
| Sevelamer restores bone volume and improves bone microarchitecture and strength in aged ovariectomized rats. | Endocrinology 20081201 |
| The CARE-2 study results: setting the record straight. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20081201 |
| Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20081201 |
| Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data. | Kidney international. Supplement 20081201 |
| A review article: sevelamer hydrochloride and metabolic acidosis in dialysis patients. | Cardiovascular & hematological disorders drug targets 20081201 |
| Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20081101 |
| Progression of calcification in the Calcium Acetate Renagel Evaluation-2 (CARE-2) Study. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20081101 |
| Hyperphosphatemia in the Calcium Acetate Renagel Evaluation-2 (CARE-2) Study. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20081101 |
| Binder wars. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20081101 |
| Effects of treatment of renal osteodystrophy on bone histology. | Clinical journal of the American Society of Nephrology : CJASN 20081101 |
| New strategies in treatment of mineral and bone disorders and associated cardiovascular disease in patients with chronic kidney disease. | Recent patents on cardiovascular drug discovery 20081101 |
| Overcoming obstacles for adherence to phosphate binding medication in dialysis patients: a qualitative study. | Pharmacy world & science : PWS 20081001 |
| Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them? | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20081001 |
| Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: methods and data comparison results. | Hemodialysis international. International Symposium on Home Hemodialysis 20081001 |
| Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate. | Therapeutics and clinical risk management 20081001 |
| Calcium load during administration of calcium carbonate or sevelamer in individuals with normal renal function. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080901 |
| Vitamin D deficiency and associated factors in hemodialysis patients. | Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20080901 |
| Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging. | The international journal of cardiovascular imaging 20080801 |
| Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis. | Therapeutics and clinical risk management 20080801 |
| Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children. | Pediatric blood & cancer 20080701 |
| Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. | Clinical journal of the American Society of Nephrology : CJASN 20080701 |
| Time-dependent effect of sevelamerHCl on the cardiovascular system. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080601 |
| Sevelamer. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080601 |
| A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20080601 |
| Buffering effects of calcium carbonate as clarified by sevelamer hydrochloride monotherapy. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20080601 |
| Sevelamer: constipation and occlusion. Complications, sometimes fatal. | Prescrire international 20080601 |
| Therapeutic strategies to slow chronic kidney disease progression. | Pediatric nephrology (Berlin, Germany) 20080501 |
| Lack of mortality benefit with sevelamer. | Kidney international 20080501 |
| Recent clinical trials of pharmacologic cardiovascular interventions in patients with chronic kidney disease. | Reviews on recent clinical trials 20080501 |
| Lower gastrointestinal bleeding: association with Sevelamer use. | World journal of gastroenterology 20080428 |
| Comparison of chronic renal failure rats and modification of the preparation protocol as a hyperphosphataemia model. | Nephrology (Carlton, Vic.) 20080401 |
| Use of sevelamer hydrochloride as an oxalate binder. | The Journal of urology 20080401 |
| Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20080401 |
| [Treatment of secondary hyperparathyroidism in renal insufficiency: role of calcitriol, sevelamer and cinacalcet]. | Revue medicale suisse 20080305 |
| The effects of conformation and solvation on optical rotation: substituted epoxides. | Chirality 20080301 |
| Ectopic mineralization of connective tissue in Abcc6-/- mice: effects of dietary modifications and a phosphate binder--a preliminary study. | Experimental dermatology 20080301 |
| K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. | Kidney international 20080301 |
| Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. | International urology and nephrology 20080301 |
| Phosphate binder choice in dialysis patients: a call for evidence-based rather than marketing-based clinical practice. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20080301 |
| A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20080301 |
| Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients. | Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20080301 |
| Total synthesis of (+)-yatakemycin. | Chemistry, an Asian journal 20080201 |
| Chronic kidney disease mineral and bone disorder in children. | Pediatric nephrology (Berlin, Germany) 20080201 |
| Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. | Journal of the American Society of Nephrology : JASN 20080201 |
| An economic evaluation of sevelamer in patients new to dialysis. | Current medical research and opinion 20080201 |
| Block randomized trial evidencing lower mortality with sevelamer compared with calcium phosphate binder in incident dialysis patients. | Kidney international 20080201 |
| Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20080201 |
| A pragmatic recipe for the treatment of hindered rotations in the vibrational averaging of molecular properties. | Chemphyschem : a European journal of chemical physics and physical chemistry 20080111 |
| Phosphate binders and timing of levothyroxine administration. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080101 |
| Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. | American journal of nephrology 20080101 |
| After several years of witchhunting, can calcium-based phosphate binding be released on probation? | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080101 |
| Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. | Clinical journal of the American Society of Nephrology : CJASN 20080101 |
| The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)-2 study. | Academic radiology 20080101 |
| Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. | Drugs 20080101 |
| Calciphylaxis of both proximal and distal distribution. | Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20080101 |
| Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. | Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20080101 |
| Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. No good evidence to promote a general use of sevelamer. | Kidney international 20080101 |
| [Basic and clinical aspects of calcimimetics. Calcimimetics from the viewpoint of medical cost]. | Clinical calcium 20080101 |
| Efficacy and side effects of sevelamer hydrochloride as sole phosphate binder in peritoneal dialysis patients with severe hyperphosphatemia. | Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20080101 |
| [Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101 |
| [Therapeutic options for mineral metabolism disorders in dialysis patients: a case report]. | Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20080101 |
| Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. | Nephron. Clinical practice 20080101 |
| Preventive measures and new pharmacological approaches of calcium and phosphate disorders. | Contributions to nephrology 20080101 |
| [Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101 |
| Endotoxin-binding affinity of sevelamer hydrochloride. | American journal of nephrology 20080101 |
| Nonphosphate-binding effects of sevelamer--are they of clinical relevance? | Seminars in dialysis 20080101 |
| Are CSN and NKF-K/DOQI mineral metabolism guidelines for hemodialysis patients achievable? Results from a provincial renal program. | CANNT journal = Journal ACITN 20080101 |
| Calcium and the saga of the binders: accumulating controversy, or building consensus? | International urology and nephrology 20080101 |
| [Clinical advances in vascular calcification]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101 |
| [Control of phosphorus and treatment with vitamin D in chronic kidney disease prior to the start of dialysis]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101 |
| [Phosphorus (P) chelant in dialysis: efficacy and cost. Peritoneal dialysis solutions]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101 |
| Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study. | Nephron. Clinical practice 20080101 |
| Switching from calcium carbonate to sevelamer hydrochloride has suppressive effects on the progression of aortic calcification in hemodialysis patients: assessment using plain chest X-ray films. | Renal failure 20080101 |
| [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101 |
| [Electrolyte and acid-base balance disorders in advanced chronic kidney disease]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101 |
| Hemipelvic osteomyelitis in a hemodialysis patient associated with methicillin-resistant Staphylococcus aureus bacteremia. | International journal of nephrology and renovascular disease 20080101 |
| Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs. | International journal of nephrology and renovascular disease 20080101 |
| Factors associated with mortality in patients new to haemodialysis. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20071201 |
| Chronic acid-base perturbations in hemodialysis patients treated with sevelamer hydrochloride: a two-year follow-up study. | Artificial organs 20071201 |
| A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. | Current medical research and opinion 20071201 |
| Survival in end stage renal disease: calcium carbonate vs. sevelamer. | Journal of clinical pharmacy and therapeutics 20071201 |
| Intractable wounds caused by calcific uremic arteriolopathy treated with bisphosphonates. | Journal of the American Academy of Dermatology 20071201 |
| Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20071201 |
| CKD-MBD: impact on management of kidney disease. | Clinical and experimental nephrology 20071201 |
| A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. | Clinical nephrology 20071201 |
| Juice powder concentrate and systemic blood pressure, progression of coronary artery calcium and antioxidant status in hypertensive subjects: a pilot study. | Evidence-based complementary and alternative medicine : eCAM 20071201 |
| Atherosclerosis and vascular calcification in uraemia - a new experimental model. | Prilozi 20071201 |
| Study probes best choice of drug to reduce phosphate in patients on dialysis. | JAMA 20071107 |
| Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. | Kidney international 20071101 |
| The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. | Kidney international 20071101 |
| Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. | Clinical journal of the American Society of Nephrology : CJASN 20071101 |
| The details bedevil DCOR. | Kidney international 20071101 |
| Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. | Journal of pharmaceutical sciences 20071001 |
| Economic evaluation of sevelamer in patients with end-stage renal disease. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20071001 |
| Effect of sevelamer on aortic pulse wave velocity in patients on hemodialysis: a prospective observational study. | Hemodialysis international. International Symposium on Home Hemodialysis 20071001 |
| Sevelamer: a promising but unproven drug. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20071001 |
| Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20071001 |
| Calcium and phosphorus control in patients undergoing hemodialysis: from the view-points of activities of daily living. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20071001 |
| Optimising the treatment of hyperphosphatemia and vascular calcification in chronic kidney disease. | Expert opinion on emerging drugs 20070901 |
| Emerging drugs for hyperphosphatemia. | Expert opinion on emerging drugs 20070901 |
| [A case of the metastatic calcification of trachea, bronchus, and lung]. | Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20070901 |
| Lipoprotein metabolism in chronic renal insufficiency. | Pediatric nephrology (Berlin, Germany) 20070801 |
| Hyperostosis with hyperphosphatemia and tumoral calcinosis: a case report. | Pediatric nephrology (Berlin, Germany) 20070801 |
| Transient acid exposure increases sevelamer HCl phosphate binding. | Journal of pharmaceutical sciences 20070801 |
| New medications which decrease levothyroxine absorption. | Thyroid : official journal of the American Thyroid Association 20070801 |
| Sevelamer and extension studies. | Kidney international 20070701 |
| Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070601 |
| Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20070601 |
| Does Sevelamer reduce mortality by slowing of progression of coronary calcification? | Kidney international 20070601 |
| [Phosphate binder up to date]. | Clinical calcium 20070501 |
| Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20070401 |
| Lanthanum: new drug. Hyperphosphataemia in dialysis patients: more potential problems than benefits. | Prescrire international 20070401 |
| Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate. | The International journal of artificial organs 20070401 |
| Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. | Kidney international 20070301 |
| Control of hyperphosphatemia beyond phosphate. | Kidney international 20070301 |
| [Arteriosclerosis and vascular calcification in chronic kidney disease (CKD) patients]. | Clinical calcium 20070301 |
| [Relationship between sevelamer HCl and vascular calcification]. | Clinical calcium 20070301 |
| Vitamin D analogs for secondary hyperparathyroidism: what does the future hold? | The Journal of steroid biochemistry and molecular biology 20070301 |
| [How to reach and maintain the K/DOQI recommendations for bone and mineral metabolism in patients undergoing haemodialysis: an efficient strategy]. | Nephrologie & therapeutique 20070301 |
| Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients. | Kidney international 20070201 |
| Potential usefulness of sevelamer hydrochloride to improve cardiac outcome in patients with coronary disease and normal renal function. | Medical hypotheses 20070101 |
| Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. | Journal of the American Society of Nephrology : JASN 20070101 |
| Effect of phosphate binders upon TSH and L-thyroxine dose in patients on thyroid replacement. | International urology and nephrology 20070101 |
| Animal models--what they can tell us about vascular calcification in CKD. | Seminars in dialysis 20070101 |
| Vascular calcification and disordered mineral metabolism in dialysis patients. | Seminars in dialysis 20070101 |
| Vascular calcification--a new window on the cardiovascular system: role of agents used to manipulate skeletal integrity. | Seminars in dialysis 20070101 |
| Final Word: The binders wars 2007-2017: 'The truth is out there somewhere...'. | Seminars in dialysis 20070101 |
| Causes and consequences of increased arterial stiffness in chronic kidney disease patients. | Kidney & blood pressure research 20070101 |
| Effect of sevelamer hydrochloride on markers of bone turnover in Japanese dialysis patients with low biointact PTH levels. | Internal medicine (Tokyo, Japan) 20070101 |
| Sevelamer and other anion-exchange resins in the prevention and treatment of hyperphosphataemia in chronic renal failure. | Nephron. Physiology 20070101 |
| Comparison of total parathyroidectomy without autotransplantation and without thymectomy versus total parathyroidectomy with autotransplantation and with thymectomy for secondary hyperparathyroidism: TOPAR PILOT-Trial. | Trials 20070101 |
| Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis. | Journal of nephrology 20070101 |
| [Either calcium carbonate or sevelamer decreases urinary oxalate excretion in chronic renal failure patients]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20070101 |
| Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study. | Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20070101 |
| Sevelamer treatment strategy in peritoneal dialysis patients: conventional dose does not make best use of resources. | Journal of nephrology 20070101 |
| Hypercalcemia after transplant nephrectomy in a hemodialysis patient: a case report. | Journal of medical case reports 20070101 |
| Synthesis of enantiopure pseudo-L-vinylcyclopropyl nucleosides bearing quaternary carbon as potential anti-herpesvirus agent. | Nucleosides, nucleotides & nucleic acids 20070101 |
| Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients. | Recent patents on cardiovascular drug discovery 20070101 |
| [K-DOQI guidelines for calcium and phosphorus metabolism in chronic kidney disease: outcomes, compliance and new drugs for treatment]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20070101 |
| End stage renal disease. | BMJ clinical evidence 20070101 |
| A new era in phosphate binder therapy: what are the options? | Kidney international. Supplement 20061201 |
| Pleiotropic effects of the non-calcium phosphate binder sevelamer. | Kidney international. Supplement 20061201 |
| Lanthanum carbonate. | Drugs of today (Barcelona, Spain : 1998) 20061201 |
| Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | Journal of molecular graphics & modelling 20061101 |
| Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20061101 |
| The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis. | The Journal of clinical endocrinology and metabolism 20061001 |
| Review of dialysate calcium concentration in hemodialysis. | Hemodialysis international. International Symposium on Home Hemodialysis 20061001 |
| Emerging strategies for lowering serum phosphorous in patients with end-stage renal disease. | Expert opinion on pharmacotherapy 20061001 |
| The safety of phosphate binders. | Expert opinion on drug safety 20060901 |
| Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20060901 |
| Phosphate binders and management of hyperphosphataemia in end-stage renal disease. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060801 |
| Novel dosage forms and regimens for sevelamer-based phosphate binders. | Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20060701 |
| The case against calcium-based phosphate binders. | Clinical journal of the American Society of Nephrology : CJASN 20060701 |
| Calcium-based phosphate binders are appropriate in chronic renal failure. | Clinical journal of the American Society of Nephrology : CJASN 20060701 |
| Total synthesis of (+)-yatakemycin. | Journal of the American Chemical Society 20060607 |
| Molecular modeling studies of the binding characteristics of phosphates to sevelamer hydrochloride--assessing a novel technique to reduce phosphates contamination. | International journal of environmental research and public health 20060601 |
| Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients. | Nature clinical practice. Nephrology 20060601 |
| Diarrhea induced by high doses of nicotinamide in dialysis patients. | Kidney international 20060501 |
| Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients. | Clinical nephrology 20060501 |
| Phosphate binders. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20060415 |
| A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20060401 |
| Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders. | Nephrology (Carlton, Vic.) 20060401 |
| Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060301 |
| Sevelamer therapy for pediatric end-stage renal disease. | Pharmacotherapy 20060301 |
| Effects of sevelamer and calcium on coronary artery calcification in patients new to dialysis: time for better controlled clinical trials. | Kidney international 20060301 |
| The CARE study and cardiovascular calcification. | Managed care (Langhorne, Pa.) 20060301 |
| Does sevelamer have greater skeletal benefit than calcium carbonate in children with secondary hyperparathyroidism? | Nature clinical practice. Nephrology 20060301 |
| Attitude of Physicians towards the Management of Bone Disease in Hemodialysis Patients: A Questionnaire Based Survey. | Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20060301 |
| Phosphate binders. | The Medical letter on drugs and therapeutics 20060213 |
| Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. | Pediatric nephrology (Berlin, Germany) 20060201 |
| Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060201 |
| Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. | Kidney international 20060201 |
| Lanthanum carbonate. | The Annals of pharmacotherapy 20060201 |
| The continuous challenge of cardiovascular and bone and bone disease in uremic patients: clinical consequences of hyperphosphatemia and advanced therapeutic approaches. | Journal of nephrology 20060101 |
| Lanthanum: a safe phosphate binder. | Seminars in dialysis 20060101 |
| Sevelamer hydrochloride in peritoneal dialysis patients: ca' canny but ca' awa'. | Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20060101 |
| Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. | Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20060101 |
| Sevelamer worsens metabolic acidosis in hemodialysis patients. | Journal of nephrology 20060101 |
| Long-term management of sevelamer hydrochloride-induced metabolic acidosis aggravation and hyperkalemia in hemodialysis patients. | Renal failure 20060101 |
| Minimizing bone abnormalities in children with renal failure. | Paediatric drugs 20060101 |
| Can discrete event simulation be of use in modelling major depression? | Cost effectiveness and resource allocation : C/E 20060101 |
| A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. | Renal failure 20060101 |
| A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. | PloS one 20060101 |
| Phosphate overload accelerates vascular aging in uremic patients. | Heart international 20060101 |
| Calciphylaxis in pediatric end-stage renal disease. | Pediatric nephrology (Berlin, Germany) 20051201 |
| Hyperphosphatemia and phosphate binders. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20051115 |
| Effect of lipid modification on progression of coronary calcification. | Journal of the American Society of Nephrology : JASN 20051101 |
| Strategies for improving long-term survival in patients with ESRD. | Journal of the American Society of Nephrology : JASN 20051101 |
| Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. | Circulation 20051101 |
| Does sevelamer have anti-atherosclerotic properties in maintenance hemodialysis patients? | Nature clinical practice. Nephrology 20051101 |
| Drug interaction between sevelamer and furosemide. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20051001 |
| Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. | Kidney international 20051001 |
| Gastric pH, sevelamer hydrochloride and omeprazole. | Clinical nephrology 20051001 |
| The effect of sevelamer on tacrolimus target levels. | Transplantation 20050915 |
| [Treatment of adynamic bone disease with the complete replacement from calcium carbonate to sevelamer hydrochloride]. | Clinical calcium 20050901 |
| [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH]. | Clinical calcium 20050901 |
| [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis]. | Clinical calcium 20050901 |
| [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease]. | Clinical calcium 20050901 |
| [Clinical analysis of time-course changes in minerals and parathyroid hormone levels during treatment with phosphate binders in hemodialysis patients with secondary hyperparathyroidism]. | Clinical calcium 20050901 |
| [Control of calcium and phosphate in hemodialysis patients]. | Clinical calcium 20050901 |
| [Relationship between serum calcium level and PTH concentration proved with sevelamer hydrochloride]. | Clinical calcium 20050901 |
| [Clinical effect of introduction of sevelamer hydrochloride in patients with hyperphosphatemia undergoing maintenance dialysis]. | Clinical calcium 20050901 |
| [Sevelamer hydrochloride and K/DOQI guidelines]. | Clinical calcium 20050901 |
| [Sevelamer hydrochloride and vitamin D for controlling serum calcium, phosphorus and bone metabolism in patients undergoing hemodialysis]. | Clinical calcium 20050901 |
| [Role of sevelamer hydrochloride in the Coronary Artery Calcification Index]. | Clinical calcium 20050901 |
| [Management of secondary hyperparathyroidism]. | Clinical calcium 20050901 |
| [Present status and problems in vitamin D and sevelamer therapy (discussion)]. | Clinical calcium 20050901 |
| Length of interdialytic interval influences serum calcium and phosphorus concentrations. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050801 |
| Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050801 |
| Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. | Journal of the American Society of Nephrology : JASN 20050801 |
| Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050801 |
| Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050801 |
| Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050801 |
| Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050801 |
| Introduction to sevelamer hydrochloride and its clinical effects. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050801 |
| Role of sevelamer hydrochloride in the coronary artery calcification score. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050801 |
| Management of secondary hyperparathyroidism. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050801 |
| Impact of sevelamer hydrochloride and the K/DOQI guidelines. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050801 |
| [Pharmacologic intervention for vascular calcification]. | Clinical calcium 20050701 |
| Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis. | Kidney international. Supplement 20050601 |
| Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD). | Kidney international. Supplement 20050601 |
| End stage renal disease. | Clinical evidence 20050601 |
| Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20050501 |
| Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. | American heart journal 20050501 |
| New strategy to attenuate pulse wave velocity in haemodialysis patients. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050401 |
| Modeling the implications of changes in vascular calcification in patients on hemodialysis. | Kidney international 20050401 |
| Economic impact of sevelamer in patients with ESRD. | Kidney international 20050401 |
| Opportunity and cost of sevelamer in dialysis patients. | Kidney international 20050401 |
| K/DOQI practice guidelines for bone metabolism and disease in chronic kidney disease: another opportunity for renal dietitians to take a leadership role in improving outcomes for patients with chronic kidney disease. | Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20050401 |
| Predictive factors of low HCO3- levels in peritoneal dialysis patients. | Clinical nephrology 20050401 |
| Vascular calcifications in chronic kidney disease: are there new treatments? | Current vascular pharmacology 20050401 |
| The therapeutic potential of novel phosphate binders. | Pediatric nephrology (Berlin, Germany) 20050301 |
| Sevelamer and pharmacokinetics of cyclosporin A after kidney transplantation. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050301 |
| Drug interaction between sevelamer and cyclosporin. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050301 |
| Sevelamer-induced acidosis. | Kidney international 20050201 |
| Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050201 |
| The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin d metabolites. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050201 |
| Is 2.5 mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050201 |
| Different routes bridging calcium in Japanese hemodialysis patients. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050201 |
| Hyperphosphatemia in renal failure. | Blood purification 20050101 |
| [Sevelamer:hydrochloride]. | Clinical calcium 20050101 |
| Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. | Arthritis and rheumatism 20050101 |
| Phosphorus management in end-stage renal disease. | Seminars in dialysis 20050101 |
| [Control of calcium and phosphate metabolism and prevention of vascular calcifications in uremic patients]. | Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20050101 |
| Plasma aluminium: a redundant test for patients on dialysis? | Annals of clinical biochemistry 20050101 |
| Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by sevelamer hydrochloride. | Renal failure 20050101 |
| Cardiovascular calcification progression -- a comparison of sevelamer and calcium-based phosphate binders. | Blood purification 20050101 |
| The clinical management of hyperphosphatemia. | Journal of nephrology 20050101 |
| [New therapy strategies in secondary hyperparathyroidism on dialysis (I): new concepts, new treatments]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20050101 |
| Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. | Renal failure 20050101 |
| Effects of efficient phosphate binding on bone in chronic renal failure rats. | Renal failure 20050101 |
| A high calcium-phosphate product is associated with high C-reactive protein concentrations in hemodialysis patients. | Nephron. Clinical practice 20050101 |
| Increase in serum magnesium level in haemodialysis patients receiving sevelamer hydrochloride. | International urology and nephrology 20050101 |
| Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20050101 |
| Peritoneal dialysis patients using sevelamer do not present the acidosis problems that hemodialysis patients do. | Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 20050101 |
| Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value. | Core evidence 20050101 |
| Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders. | Nephrology (Carlton, Vic.) 20041201 |
| The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20041001 |
| Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? | Kidney international 20041001 |
| [New aspects in the management of renal osteodystrophy]. | Polskie Archiwum Medycyny Wewnetrznej 20041001 |
| Pathophysiology of vascular calcification in chronic kidney disease. | Circulation research 20040917 |
| Cardiovascular calcification in patients with chronic renal failure: are we on target with this risk factor? | Kidney international. Supplement 20040901 |
| Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. | Kidney international. Supplement 20040901 |
| A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. | Kidney international 20040901 |
| Arterial calcification in chronic kidney disease. | Seminars in nephrology 20040901 |
| Management of calcium and bone abnormalities in hemodialysis patients. | Seminars in nephrology 20040901 |
| [Prophylaxis and treatment of adynamic bone]. | Clinical calcium 20040901 |
| [Evolution in vitamin D treatment after debut of sevelamer hydrochloride in chronic renal failure patients]. | Clinical calcium 20040901 |
| Phosphate binders in dialyzed patients: efficacy and cost. | Pediatric nephrology (Berlin, Germany) 20040801 |
| Vascular calcification in patients with end-stage renal disease. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20040801 |
| Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification. | Clinical nephrology 20040801 |
| Dietary phosphorus reduction by pretreatment of human breast milk with sevelamer. | Pediatric nephrology (Berlin, Germany) 20040701 |
| Drug interaction between sevelamer and cyclosporin. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20040701 |
| The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia. | Current medical research and opinion 20040701 |
| Determination of the binding parameter constants of Renagel capsules and tablets at pH 7 by high performance capillary electrophoresis. | Journal of pharmaceutical and biomedical analysis 20040629 |
| Determinants of progressive vascular calcification in haemodialysis patients. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20040601 |
| Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. | Saudi medical journal 20040601 |
| [Treatment for chronic kidney failure with cerebrovascular disease]. | Nihon rinsho. Japanese journal of clinical medicine 20040601 |
| [Ischemic heart disease]. | Nihon rinsho. Japanese journal of clinical medicine 20040601 |
| [Evaluation of coronary artery calcification in ESRD patients]. | Clinical calcium 20040601 |
| [Sevelamer hydrochloride prevents ectopic calcification of blood vessels]. | Clinical calcium 20040601 |
| Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). | Kidney international 20040501 |
| [Phosphate binding therapy]. | Nihon rinsho. Japanese journal of clinical medicine 20040501 |
| [Outlines of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease]. | Clinical calcium 20040501 |
| [Treatment of bone disease in chronic kidney disease and in renal transplant recipients under K/DOQI clinical practice guidelines]. | Clinical calcium 20040501 |
| [Clinical evidence and treatment for optimum concentration of parathyroid hormone, calcium and phosphate in chronic renal failure]. | Clinical calcium 20040501 |
| [Mechanism and therapy of vascular calcification]. | Clinical calcium 20040501 |
| [Front line of management of hyperphosphatemia in hemodialysis patients]. | Clinical calcium 20040501 |
| Nephrogenic fibrosing dermopathy in pediatric patients. | Pediatric nephrology (Berlin, Germany) 20040401 |
| Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20040301 |
| Improving phosphate-binder therapy as a way forward. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20040301 |
| Drug interaction between sevelamer and cyclosporin. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20040201 |
| [Skeletal complications of renal insufficiency]. | Nihon rinsho. Japanese journal of clinical medicine 20040201 |
| An unusual case of calciphylaxis. | Journal of cutaneous medicine and surgery 20040101 |
| Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. | The Journal of heart valve disease 20040101 |
| Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly. | Drugs & aging 20040101 |
| Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients. | Nephron. Clinical practice 20040101 |
| [Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20040101 |
| [Disturbances of mineral metabolism and vascular calcifications in dialysis patients (review)]. | Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20040101 |
| [The treatment of osteodystrophy in dialyzed uremic patients: results of the first Sardinian audit]. | Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20040101 |
| BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991]. | BMC nephrology 20040101 |
| Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure. | Seminars in dialysis 20040101 |
| Sevelamer hydrochloride: an effective phosphate binder in dialyzed children. | Pediatric nephrology (Berlin, Germany) 20031201 |
| Sevelamer: where are the data? | Kidney international 20031201 |
| Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20031201 |
| Construction of a cis-cyclopropane via reductive radical decarboxylation. Enantioselective synthesis of cis- and trans-1-arylpiperazyl-2-phenylcyclopropanes designed as antidopaminergic agents. | The Journal of organic chemistry 20031128 |
| Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. | Kidney international 20031101 |
| [Pharmacological and clinical trial data on a novel phosphate-binding polymer (sevelamer hydrochloride), a medicine for hyperphosphatemia in hemodialysis patients]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20031101 |
| Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20031001 |
| Calcium-containing phosphate binder use associated with accelerated atherosclerotic coronary calcification. | Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20031001 |
| Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. | Journal of the American Society of Nephrology : JASN 20030901 |
| Slowing the progression of vascular calcification in hemodialysis. | Journal of the American Society of Nephrology : JASN 20030901 |
| Impact of dyslipidemia in end-stage renal disease. | Journal of the American Society of Nephrology : JASN 20030901 |
| Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. | Kidney international 20030801 |
| Affinity labeling of a single guanine bulge. | Journal of the American Chemical Society 20030730 |
| Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients. | Current opinion in nephrology and hypertension 20030701 |
| Prevention and treatment of secondary hyperparathyroidism: still a challenge for the nephrologist? | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20030701 |
| Hyperphosphataemia and treatment with sevelamer in haemodialysis patients. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20030701 |
| Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate. | Kidney international. Supplement 20030601 |
| Medical management of secondary hyperparathyroidism in chronic renal failure. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20030601 |
| Sevelamer hydrochloride, a calcium-free phosphate binder, inhibits parathyroid cell proliferation in partially nephrectomized rats. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20030601 |
| Phosphate binder usage in kidney failure patients. | Expert opinion on pharmacotherapy 20030601 |
| A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. | Clinical nephrology 20030601 |
| Management of hyperphosphataemia in chronic renal disease: lessons from the past and future directions. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20030401 |
| The renal dietitian's role in managing hyperphosphatemia and secondary hyperparathyroidism in dialysis patients: a national survey. | Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20030401 |
| Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. | Advances in renal replacement therapy 20030401 |
| Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20030301 |
| New strategies for the treatment of secondary hyperparathyroidism. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20030301 |
| Calcium on trial: beyond a reasonable doubt? | Kidney international 20030101 |
| Calcium on trial: beyond a reasonable doubt? | Kidney international 20030101 |
| Hyperphosphataemia in renal failure: causes, consequences and current management. | Drugs 20030101 |
| [Critical appraisal of sevelamer for the treatment of hyperphosphatemia in patients with chronic renal failure]. | Revista da Associacao Medica Brasileira (1992) 20030101 |
| Vascular calcification in chronic renal failure. | Nephron. Clinical practice 20030101 |
| [Management of hyperphosphoremia]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20030101 |
| Sevelamer. | Nephron. Clinical practice 20030101 |
| The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. | American journal of nephrology 20030101 |
| Safety of new phosphate binders for chronic renal failure. | Drug safety 20030101 |
| [Experience with sevelamer in peritoneal dialysis]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20030101 |
| [Renal osteodystrophy Guidelines]. | Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20030101 |
| Medication-related problem type and appearance rate in ambulatory hemodialysis patients. | BMC nephrology 20030101 |
| Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients. | Journal of nephrology 20030101 |
| Oral calcium, sevelamer and vascular calcification in uraemic patients. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20021201 |
| Pathophysiology and recent advances in the management of renal osteodystrophy. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20021201 |
| Recent advances in nephrology: highlights from the 35th annual meeting of the American society of nephrology. | Drugs of today (Barcelona, Spain : 1998) 20021201 |
| Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. | Nephron 20021001 |
| Effect of phosphate binders on supplemental iron absorption in healthy subjects. | Journal of clinical pharmacology 20021001 |
| The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. | Journal of the American Society of Nephrology : JASN 20020901 |
| A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20020901 |
| Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca x P product and aggressive wound care. | Clinical nephrology 20020901 |
| Bile acid binding to sevelamer HCl. | Kidney international 20020801 |
| Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. | Kidney international 20020701 |
| Determination of the binding parameter constants of Renagel capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography. | Journal of pharmaceutical and biomedical analysis 20020620 |
| The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20020201 |
| Revision of absolute configuration of enantiomeric (methylenecyclopropyl)carbinols obtained from (R)-(-)- and (S)-(+)-epichlorohydrin and methylenetriphenylphosphorane. Implications for reaction mechanism and improved synthesis of antiviral methylenecyclopropane analogues of nucleosides. | The Journal of organic chemistry 20020111 |
| Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethics. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20020101 |
| Sevelamer, a phosphate-binding polymer, is a non-absorbed compound. | Clinical pharmacokinetics 20020101 |
| RenaGel efficacy in severe secondary hyperparathyroidism. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20020101 |
| Treatment with sevelamer decreases bicarbonate levels in peritoneal dialysis patients. | Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20020101 |
| Renal mineral handling in normal rats treated with sevelamer hydrochloride (Renagel), a noncalcemic phosphate binder. | Nephron 20011101 |
| New approaches to the treatment of calcium and phosphorus abnormalities in patients on hemodialysis. | Current opinion in nephrology and hypertension 20011101 |
| [Control of the secondary hyperparathyroidism by the suppression of plasma phosphate level in chronic renal failure patients]. | Clinical calcium 20011001 |
| Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20010901 |
| Sevelamer, Ca x P product and vitamin D. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20010201 |
| Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics. | Journal of clinical pharmacology 20010201 |
| Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers. | Journal of clinical pharmacology 20010201 |
| Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients. | Journal of nephrology 20010101 |